CardioKinetix Inc. Announces Late Breaking EuroPCR Session Featuring First-of-Its-Kind Minimally Invasive Treatment for Heart Failure
5/7/2012 9:48:18 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute™ Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.
comments powered by